AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by CIBC Asset Management Inc

CIBC Asset Management Inc increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 2.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 238,268 shares of the company’s stock after buying an additional 5,269 shares during the period. CIBC Asset Management Inc’s holdings in AstraZeneca were worth $18,563,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. McClarren Financial Advisors Inc. increased its stake in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. acquired a new position in AstraZeneca during the 2nd quarter worth $26,000. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca in the third quarter worth $28,000. Pathway Financial Advisers LLC acquired a new position in AstraZeneca during the 1st quarter valued at about $29,000. Finally, CANADA LIFE ASSURANCE Co raised its position in shares of AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after buying an additional 146 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Down 2.8 %

AZN stock opened at $63.23 on Friday. The company has a 50 day moving average of $75.03 and a two-hundred day moving average of $78.20. The company has a quick ratio of 0.69, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a market cap of $196.05 billion, a price-to-earnings ratio of 30.25, a PEG ratio of 1.20 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period last year, the business earned $0.87 EPS. On average, equities analysts anticipate that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, TD Cowen increased their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.